Actively Recruiting
Pharmacist-Led Continuous Glucose Monitoring for Prediabetes
Led by University of South Florida · Updated on 2026-05-11
40
Participants Needed
2
Research Sites
60 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to determine if a pharmacist-led program involving continuous glucose monitoring (CGM) improves glucose control and health behavior in people with prediabetes. The main questions it aims to answer are: 1. Determine impact of pharmacist-led CGM on glycemic control in people with prediabetes. Researchers will compare change in hemoglobin A1c at 12 weeks with pharmacist-led CGM versus a historical cohort of subjects with prediabetes receiving no CGM. The investigators will also assess change in CGM-derived glycemic metrics from baseline to end of the CGM wear period in the intervention group. 2. Evaluate impact of pharmacist-led CGM on health behavior change in people with prediabetes in the intervention group. Participants will be asked to complete the Summary of Diabetes Self-Care Activities Measure (SDSCA) and 36-Item Short Form Health Survey (SF-36) at baseline, at the end of week 4, and at the end of the study so that researchers can measure the effects in the intervention group on health behavior change.
CONDITIONS
Official Title
Pharmacist-Led Continuous Glucose Monitoring for Prediabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 to 70 years of age
- Diagnosed with prediabetes (HbA1c 5.7-6.4%)
- Have a compatible smartphone with the Dexcom Stelo sensor system
- Have not worn a continuous glucose monitor (CGM) in the last 6 months before enrollment
You will not qualify if you...
- Diagnosis of any form of diabetes other than prediabetes, including type 1, type 2, monogenic, cystic fibrosis-related, post-transplant, or latent autoimmune diabetes
- Problematic hypoglycemia in the prior 6 months, defined as recurrent level 2 hypoglycemic events (glucose <54 mg/dL) despite treatment adjustments, or any level 3 hypoglycemic event requiring third-party assistance
- Pregnant or planning pregnancy during the study timeframe
- Currently receiving or planned to receive dialysis during the study timeframe
- Current use of systemic steroids for any condition
- Known allergy to medical grade adhesives
- Use of any CGM device in the past 6 months
- History of a diagnosed eating disorder
- Current use of second-generation antipsychotic medications at the time of consent
- Lack of capacity to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
USF Health Department of Family Medicine - Morsani Center for Advanced Health Care
Tampa, Florida, United States, 33612
Actively Recruiting
2
USF Health Department of Family Medicine - University Partnership Center
Tampa, Florida, United States, 33613
Actively Recruiting
Research Team
K
Kevin Cowart, PharmD, MPH
CONTACT
R
Raechel White, PharmD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here